Preview

Rational Pharmacotherapy in Cardiology

Advanced search

NEW POSSIBILITIES FOR EVALUATION OF SEVERITY AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE BASED ON N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE PLASMA LEVEL

https://doi.org/10.20996/1819-6446-2009-5-5-17-21

Full Text:

Abstract

Aim. To study an importance of plasma N-terminal pro-brain natriuretic peptide (N-proBNP) in evaluation of severity and prognosis in patients with chronic heart failure (CHF) of ischemic genesis.

Material and methods. 77 patients (60 men and 17 women; 59,4±10,7 y.o.) with CHF of ischemic genesis were included in the study. All patients had sinus rhythm and history of Q wave myocardial infarction. Standard examination was performed to all patients. Besides N-proBNP plasma level and patients yearly survival were evaluated.

Results. N-proBNP plasma level had direct correlation with clinical indices (exercise tolerance, blood pressure, heart rate) and echocardiographic heart sizes. N-proBNP plasma level had relationship with prognosis of CHF patients. Baseline N-proBNP level was more than 2 times higher in died patients in comparison with survived patients. The yearly survival rate of CHF patients was 51,3% if N-proBNP level had been more than 400 fmol/ml (>15% of normal value). The clinico-laboratory index (based on N-proBNP plasma level) of severity and prognosis in CHF patients was developed.

Conclusion. The clinico-laboratory index based on N-proBNP plasma level is easy to use and can improve medical practice.

About the Authors

A. S. Galjavich
Kazan State Medical University
Russian Federation
Butlerova ul. 49, Kazan, Republic of Tatarstan, 420012


S. N. Merjasev
Nizhnekamsk Central District Hospital
Russian Federation
Akhtubinskaya ul. 11, Nizhnekamsk, Republic of Tatarstan, 423570


R. A. Galjavi
Kazan State Medical University
Russian Federation
Butlerova ul. 49, Kazan, Republic of Tatarstan, 420012


R. F. Merjaseva
Nizhnekamsk Central District Hospital
Russian Federation
Akhtubinskaya ul. 11, Nizhnekamsk, Republic of Tatarstan, 423570


References

1. Groenning B.A., Nilsson J.C., Sondergaard L. et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002;143(5):923-9.

2. Gardner R.S., Ozalp F., Murday A.J. et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24(19):1735-43.

3. Gustafsson F., Badskjær J., Hansen F.S. et al. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2003;3:141-6.

4. Anand I.S., Fisher L.D., Chiang Y.T. et al. for the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107(9):1278- 83.

5. Kirk V., Bay M., Parner J. et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004;6(3):335-41.

6. Mancini D., Eisen H., Kussmaul W. et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83(3):778-86.

7. Cohn J.N., Levine T.B., Olivari M.T. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311(13):819-23.

8. Cohn J.N., Johnson G.R., Shabetai R. et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 Suppl):VI-5-16.

9. Francis G.S., Goldsmith S.R., Levine T.B. et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101(3):370-7. 10. Packer M. Neurohumoral interactions and adaptations in congestive heart failure. Circulation 1988;77(4):721-30.

10. Remes J., Tikkanen I., Fyhrquist F., Pyörälä K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991;65(5):249-55.

11. Brooksby P., Batin P., Nolan J. et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Eur Heart J 1999;20(18):1335-41.

12. Spargias K.S., Lindsay S.J., Kawar G.I. et al. QT dispersion as a predictor of longterm mortality in patients with acute myocardial infarction and clinical evidence of heart failure. Eur Heart J 1999;20(16):1158-65.

13. Mancini D.M., Wong K.L., Simson M.B. Prognostic value of an abnormal signalaveraged electrocardiogram in patients with nonischemic congestive cardiomyopathy. Circulation 1993;87(4):1083-92.

14. Aaronson K.D., Schwartz J.S., Chen T.M. et al. Development and Prospective Validation of a Clinical Index to Predict Survival in Ambulatory Patients Referred for Cardiac Transplant Evaluation. Circulation 1997;95(12):2660-7.

15. Kearney M.T., Nolan J., Lee A.J. et al. A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilized on angiotensin converting enzyme inhibitors. Eur J Heart Fail 2003;5(4):489-97.


For citation:


Galjavich A.S., Merjasev S.N., Galjavi R.A., Merjaseva R.F. NEW POSSIBILITIES FOR EVALUATION OF SEVERITY AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE BASED ON N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE PLASMA LEVEL. Rational Pharmacotherapy in Cardiology. 2009;5(5):17-21. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-5-17-21

Views: 256


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)